Alnylam to Invest US$250 Million to Expand RNAi Manufacturing Facility in Massachusetts, USA
Introduction:
Alnylam Pharmaceuticals has announced plans to invest US$250 million to expand its manufacturing facility in Norton, Massachusetts, USA.
Features:
The 200,000 sq. ft. facility in Norton, Massachusetts, will be upgraded to expand manufacturing activities.
A dedicated siRNA enzymatic-ligation platform will be established to support both clinical and commercial production of RNAi therapeutics.
The platform has been accepted into the U.S. FDA’s Emerging Technology Program for regulatory discussions related to oligonucleotide manufacturing methods.
The facility will manufacture clinical and commercial supplies of RNAi-based medicines.
Pilot-scale testing of the platform has been conducted with candidates including zilebesiran and nucresiran.
The enzymatic ligation process combines RNA fragments (“blockmers”) into complete molecules, reducing processing time and the use of organic solvents.
The upgraded facility is expected to be fully operational by late 2027.
Specifications:
| Name | Alnylam Pharmaceuticals |
| Type | New Construction |
| Budget | US$250 million |
| Year | 2027 |
